Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
暂无分享,去创建一个
M. Caligiuri | M. Grever | J. Byrd | J. Gribben | R. Larson | N. Heerema | G. Lozanski | B. Peterson | D. Lucas | B. Lampson